EU regulators to review Sandoz’ Neulasta biosimilar

30th October 2017 Uncategorised 0

The European Medicines Agency has accepted for review Novartis unit Sandoz’ biosimilar of Amgen’s Neulasta.

More: EU regulators to review Sandoz’ Neulasta biosimilar
Source: News